B7‑H3‑Targeted Antibody Reagents: Investigating a Dual‑Function Immune Modulatory Molecule in Tumour Immunology

Molecular Architecture and Expression Landscapes of B7‑H3 (CD276) for Basic Research

B7‑H3, also annotated as CD276, belongs to the B7 immune co‑signal superfamily and is classified as a type‑I transmembrane glycoprotein. Its human extracellular domain contains two paired immunoglobulin‑like variable and constant segments, setting it apart from most other B7‑family members. Distinct from well‑characterized checkpoints such as PD‑L1, the endogenous binding partners for B7‑H3 remain unconfirmed within current research datasets.

Widely detectable B7‑H3 messenger‑RNA signals appear across multiple tissue types, yet protein abundance is subject to strict post‑translational regulatory control under physiological conditions. Baseline protein expression localizes mainly to fibroblasts, endothelial cells, osteoblasts, activated antigen‑presenting cells and NK cell populations.

Multiple tumour‑derived experimental samples exhibit pronounced B7‑H3 protein overexpression, including melanoma, lung, prostate, colorectal and pancreatic tumour model materials. Higher B7‑H3 protein levels correlate with readouts for tumour progression, metastatic potential and recurrence events in retrospective laboratory analyses. Such differential expression profiles draw consistent research interest toward this immunomodulatory molecule.

Functional Paradox: Context‑Dependent Co‑Stimulatory versus Co‑Inhibitory Bioactivities

Published research records document conflicting observations describing opposing immunological outputs triggered by B7‑H3 molecular engagement. Early in‑vitro experimental evidence pointed toward co‑stimulatory properties under defined culture conditions. In the presence of anti‑CD3 stimulation, B7‑H3 exposure supports CD4⁺ and CD8⁺ T‑cell proliferation alongside elevated interferon‑γ production in cell‑based assay systems.

Accumulated later experimental datasets favour a co‑inhibitory role for B7‑H3 within tumour‑bearing model systems. B7‑H3 exposure can suppress T‑cell proliferation and reduce secretion of key effector cytokines IL‑2 and IFN‑γ in these assay settings. Within tumour‑bearing animal models, B7‑H3 contributes to tumour expansion and immune‑evasion phenotypic outputs.

At intracellular signalling levels, B7‑H3 can dampen the activation of transcription factors NFAT, AP‑1 and NF‑κB to constrain T‑cell‑mediated immune responses. Multiple variables may account for these divergent experimental observations. These variables include unidentified ligand‑receptor pairing events, varied cell‑type compositions and conformational shifts triggered by distinct local immune microenvironment conditions.

Research Workflows Enabled by B7‑H3‑Specific Antibody Reagents

Antibody reagents targeting B7‑H3 serve versatile purposes spanning molecular profiling to pre‑clinical prototype assessment in laboratory settings. Researchers deploy these antibodies to quantify B7‑H3 protein abundance within preserved tumour tissues and isolated immune‑cell populations. Expression datasets can then be cross‑referenced against phenotypic parameters collected from parallel experimental groups.

Functional laboratory assays make use of anti‑B7‑H3 antibodies to dissect signalling cascades that shape T‑cell and NK‑cell functional performance. In translational‑oriented basic‑research pipelines, multiple molecular formats targeting B7‑H3 undergo pre‑clinical laboratory evaluation. These formats include monoclonal antibodies, antibody‑drug conjugates, bispecific constructs and CAR‑engineered cell prototypes.

B7‑H3‑directed antibody‑drug‑conjugate prototypes deliver cytotoxic payloads toward B7‑H3‑positive tumour cells within pre‑clinical model systems. CAR‑T experimental constructs targeting B7‑H3 are assessed using tumour model materials representing neuroblastoma and sarcoma pathologies. All these research workflows depend on validated detection antibodies for consistent target‑expression profiling.

Recombinant Antibody Portfolio from ANT BIO PTE. LTD. Supporting B7‑H3‑Focused Tumour Immunology Studies

ANT BIO PTE. LTD. supplies recombinant rabbit monoclonal antibody clones that specifically recognize human B7‑H3 (CD276) protein targets. Clone SDT‑1333‑8 and clone SDT‑249‑26 have completed target‑specific validation and rigorous batch‑consistency quality‑control workflows during production.

Validated laboratory‑use platforms cover Western blot analysis, immunohistochemical tissue staining and flow‑cytometry cell‑surface marker profiling. These reagents support experimental tasks including tumour‑microenvironment characterization, B7‑H3‑related signalling mechanism exploration and target‑prototype profiling for immunology‑oriented basic‑research projects. PBS‑only buffer variants are also available for users requiring further buffer‑exchange experimental processing.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.